billion
peopl
worldwid
infect
hepat
b
viru
hbv
million
chronic
infect
signific
fraction
chronic
infect
individu
develop
liver
cirrhosi
hepatocellular
carcinoma
approxim
million
die
annual
hbvinduc
liver
diseas
hbv
small
envelop
dna
viru
belong
hepadnavirida
famili
replic
preferenti
liver
cell
util
uniqu
replic
strategi
involv
revers
transcript
pregenom
rna
pgrna
interferon
ifn
sever
nucleo
ide
analog
includ
lamivudin
lmv
adefovir
dipivoxil
adv
entecavir
etv
tenofovir
tdf
telbivudin
ldt
approv
treatment
chronic
hepat
b
chb
countri
low
respons
rate
side
effect
associ
ifn
mean
nucleo
ide
analog
use
often
nucleo
ide
analog
inhibit
revers
transcriptas
rt
activ
hbv
dna
polymeras
p
therebi
interrupt
elong
newli
synthes
dna
drug
also
lower
alanin
aminotransferas
level
reduc
serum
hbv
dna
level
induc
seroconvers
hbv
e
antigen
hbeag
antihb
chb
patient
lmv
first
nucleosid
analog
licens
howev
patient
becom
resist
year
therapi
common
mutat
associ
lmv
resist
substitut
methionin
isoleucin
valin
serin
ymdd
activ
site
motif
within
p
protein
rt
domain
mutat
first
detect
patient
sever
hepat
appar
lmv
failur
mutat
residu
also
contribut
lmv
resist
mutat
associ
lmv
ldt
resist
also
confer
crossresist
lnucleosid
reduc
sensit
etv
adv
tdf
advresist
also
becom
limit
factor
treatment
although
develop
slowli
resist
lmv
like
adv
tdf
methyl
deriv
adv
exhibit
antivir
activ
lmvresist
hbv
although
potent
adv
rate
emerg
resist
mutant
slower
howev
high
dose
tdf
adv
caus
nephrotox
chb
patient
also
nucleo
ide
analog
prevent
initi
format
coval
close
circular
dna
new
cell
infect
therapi
due
persist
viremia
sever
molecul
phenylpropenamid
deriv
heteroarylpyrimidin
hap
develop
circumv
drugresist
chb
phenylpropenamid
deriv
inhibit
encapsid
hbv
wildtyp
wt
lmvresist
mutant
pgrna
vitro
howev
clinic
trial
discontinu
due
toxic
phase
clinic
trial
hap
inhibit
hbv
core
c
protein
dimer
block
nucleocapsid
format
conduct
rnai
inhibitor
newli
identifi
hbv
receptor
sodium
taurochol
polypeptid
test
asian
countri
tradit
medicin
herbal
extract
use
treat
chronic
liver
diseas
thousand
year
modern
technolog
confirm
efficaci
sinc
herbal
extract
use
million
peopl
thousand
year
safeti
low
toxic
strong
asset
sever
studi
describ
antihbv
activ
tradit
herbal
extract
exampl
chlorogen
acid
quinic
acid
caffeic
acid
leav
fruit
coffe
plant
curcuma
longa
linn
extract
jasminum
officinal
l
var
grandiflorum
emodin
oxymatrin
sophora
radix
wogonin
scutellaria
baicalensi
georgi
suppress
hbv
replic
vitro
andor
vivo
phyllanthu
speci
phyllanthacea
famili
use
treat
number
diseas
includ
human
bone
disord
diabet
show
antivir
activ
human
immunodefici
viru
hbv
phyllanthu
inhibit
activ
hepadnavir
p
protein
secret
hbsag
transcript
mrna
surfac
protein
specif
interact
hbv
enhanc
promot
also
inhibit
viral
entri
viral
assembl
virion
releas
induc
express
annexin
result
indic
phyllanthu
urinaria
koreani
extract
inhibit
hbv
dna
synthesi
hbsag
hbcag
secret
lmvresist
hbv
mutant
vitro
also
evid
result
occur
via
inhibit
core
particl
format
pgrna
encapsid
increas
express
mrna
extracttr
cell
contain
replic
hbv
may
due
induct
retino
acid
induc
genei
rigi
tolllik
receptor
myeloid
differenti
primari
respons
gene
andor
tumor
necrosi
factor
receptorassoci
factor
express
taken
togeth
suggest
phyllanthu
extract
inhibit
hbv
replic
hbv
wt
lmvresistantinfect
cell
via
signal
pathway
phyllanthu
urinaria
koreani
provid
hepaguard
research
laboratori
co
dri
leaf
phyllanthu
ground
extract
water
accord
method
describ
shin
et
al
aqueou
extract
dri
powder
dissolv
phosphat
buffer
salin
final
concentr
mgml
store
requir
skin
biotechnolog
center
kyung
hee
univers
determin
chemic
composit
extract
liquid
chromatographyquadrupl
timeofflight
mass
spectrometri
lcqtofm
fig
fulllength
monomer
hbv
genom
pcramplifi
subclon
sac
isap
site
pbluescript
sk
promega
gener
pbluescripthbv
wt
ymdd
rt
activ
site
mutant
construct
pcrderiv
mutagenesi
gener
replic
compet
hbv
wt
mutant
ecor
isac
ii
fragment
pbluescripthbv
wt
variou
ymdd
mutant
insert
ppb
partial
redund
wt
hbv
subtyp
adw
plasmid
gener
ysdd
variant
met
atg
chang
ser
tcg
use
fusion
pcr
techniqu
pcrderiv
dna
fragment
gener
use
mutagen
primer
pair
cag
tta
ttcgga
tga
tgt
ggt
att
g
ca
aac
cga
aag
tca
ata
agc
cta
cta
cac
mutat
sequenc
bold
underlin
digest
xcm
isac
ii
insert
hbv
wt
construct
yield
ysdd
mutant
construct
contain
pcrderiv
dna
fragment
sequenc
confirm
presenc
specif
mutat
absenc
extran
mutat
introduc
pcr
reaction
cell
hepatocellular
carcinoma
cell
line
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
life
technolog
grand
island
ny
usa
supplement
heat
inactiv
fetal
bovin
serum
penicillinstreptomycin
humidifi
atmospher
contain
cell
transfect
hbv
wt
mutant
construct
use
lipofectamin
invitrogen
carlsbad
ca
usa
accord
manufactur
instruct
cytoplasm
core
particl
prepar
day
posttransfect
previous
describ
transfect
experi
repeat
minimum
three
time
analyz
hbv
dna
synthesi
southern
blot
hbv
dna
extract
isol
core
particl
separ
agaros
gel
electrophoresi
hybrid
randomprim
probe
specif
fulllength
hbv
sequenc
describ
previous
rel
intens
hbv
doublestrand
linear
dl
dna
measur
use
fujifilm
imag
gaug
program
fuji
film
scienc
lab
isol
core
particl
electrophores
nativ
agaros
gel
transfer
polyvinyliden
fluorid
pvdf
membran
immunoblot
polyclon
rabbit
antihbc
antibodi
dako
glostrup
denmark
describ
previous
bound
antibodi
detect
horseradishperoxidas
hrp
conjug
antirabbit
secondari
antibodi
dako
follow
enhanc
chemiluminesc
ecl
amersham
piscataway
nj
usa
total
cell
lysat
subject
sdspage
resolv
protein
transfer
pvdf
membran
membran
incub
monoclon
mous
antitubulin
calbiochem
san
diego
ca
usa
polyclon
rabbit
santa
cruz
biotechnolog
santa
cruz
ca
usa
polyclon
rabbit
antiextracellular
signalregul
kinas
erk
antiperk
cell
signal
technolog
danver
usa
polyclon
rabbit
anticjun
ntermin
kinas
jnk
antipjnk
cell
signal
technolog
polyclon
rabbit
cell
signal
technolog
polyclon
rabbit
antiluciferas
santa
cruz
biotechnolog
antibodi
immunoreact
band
visual
use
hrpconjug
secondari
antibodi
dako
follow
ecl
rel
band
intens
measur
use
fujifilm
imag
gaug
program
rpa
perform
describ
previous
analyz
encapsid
cytoplasm
pgrna
radiolabel
antisens
probe
nucleotid
nt
nt
hbv
sequenc
synthes
vitro
protect
sequenc
compris
nt
rel
level
cytoplasm
pgrna
pgrna
obtain
isol
core
particl
measur
use
fujifilm
imag
gaug
program
mtt
bromid
assay
perform
examin
cytotox
effect
extract
cell
cell
grown
micropl
incub
serial
dilut
extract
h
cell
viabil
examin
replac
cultur
medium
mtt
dmem
h
dimethyl
sulfoxid
ad
dissolv
formazan
mtt
absorb
nm
measur
plate
reader
defin
concentr
extract
reduc
cell
viabil
control
calcul
hbv
dna
extract
isol
intracellular
core
particl
analyz
realtim
quantit
pcr
abi
pcr
primer
forward
primer
hbv
gac
cac
caa
atg
ccc
cta
revers
primer
hbv
gag
att
gag
atc
ttc
tgc
encompass
nt
overlap
c
protein
cterminu
p
protein
nterminu
cycl
program
follow
denatur
follow
cycl
reaction
perform
well
pcr
plate
volum
hbv
dna
quantifi
use
standard
curv
standard
curv
construct
serial
dilut
hbv
wt
plasmid
known
molecular
weight
copi
number
total
rna
extract
cell
use
rna
isoplu
takara
otsu
shiga
japan
accord
manufactur
instruct
realtim
rtpcr
perform
measur
amount
oa
pkr
rigi
gene
mrna
briefli
rna
revers
transcrib
use
oligodt
cdna
subject
quantit
realtim
pcr
primer
use
realtim
pcr
realtim
rtpcr
list
addit
file
amount
four
major
compon
phyllanthu
extract
corilagin
gallic
acid
quercetin
geraniin
determin
lcqtofm
previous
describ
agreement
previou
report
corilagin
detect
major
peak
gallic
acid
also
detect
peak
small
fig
howev
could
detect
quercetin
mw
geraniin
mw
unabl
identifi
major
peak
shown
fig
could
exclud
possibl
quercetin
geraniin
may
respons
antihbv
activ
phyllanthu
extract
sinc
could
identifi
major
peak
specif
compound
may
therefor
play
role
antihbv
activ
next
examin
hbv
c
protein
express
core
particl
format
pgrna
express
encapsid
hbsag
hbcag
secret
dna
synthesi
hbv
wttransfectedphyllanthu
extracttr
cell
fig
agreement
previou
report
treat
cell
differ
concentr
extract
led
dosedepend
reduct
intracellular
hbv
dna
synthesi
level
hbsag
hbcag
secret
fig
lane
treatment
lmv
led
signific
reduct
hbv
dna
synthesi
fig
lane
without
affect
secret
hbsag
hbcag
fig
lane
known
whether
phyllanthu
extract
affect
c
protein
express
core
particl
format
pgrna
encapsid
therefor
next
examin
paramet
hbv
wttransfectedextracttr
cell
fig
note
pgrna
transcript
wt
lmvresist
mutant
control
cytomegaloviru
immedi
earli
cmv
ie
promot
authent
precorecor
promot
pgrna
express
affect
exposur
extract
even
though
secret
hbcag
fell
upon
exposur
extract
neither
c
protein
express
core
particl
format
affect
fig
also
pgrna
encapsid
affect
fig
result
suggest
phyllanthu
extract
inhibit
hbv
dna
synthesi
secret
hbsag
hbcag
without
affect
core
particl
format
pgrna
encapsid
next
perform
mtt
assay
determin
cytotox
concentr
phyllanthu
extract
cell
mean
extract
addit
file
much
higher
cell
addit
file
next
determin
effect
concentr
phyllanthu
extract
respect
hbv
wt
dna
synthesi
cell
h
posttransfect
h
extract
treatment
afterward
southern
blot
perform
measur
hbv
dna
level
hbv
wttransfectedextracttr
cell
level
doublestrand
linear
dl
hbv
dna
quantifi
use
imag
gaug
respect
tabl
select
index
si
hbv
wt
dna
tabl
extract
respect
hbsag
hbcag
secret
respect
determin
enzymelink
immunosorb
assay
elisa
si
hbsag
hbcag
secret
respect
tabl
southern
blot
result
agreement
obtain
realtim
pcr
tabl
conserv
motif
within
rt
catalyt
c
subdomain
hbv
p
protein
respons
rna
dnadepend
dna
polymeras
activ
frequent
observ
mutat
region
confer
resist
lmv
ldt
etv
less
frequent
observ
mutat
follow
lmv
treatment
although
addit
mutat
found
differ
rt
region
investig
inhibitori
effect
phyllanthu
extract
lmvresist
mutant
substitut
methionin
alanin
isoleucin
lysin
leucin
arginin
serin
threonin
valin
gener
yadd
yidd
ykdd
yldd
yrdd
ysdd
ytdd
yvdd
respect
fig
examin
replic
mutant
southern
blot
analysi
fig
top
panel
singlestrand
ss
dl
partial
doublestrand
relax
circular
rc
hbv
dna
molecul
detect
hbv
wt
mutanttransfect
cell
albeit
differ
replic
effici
fig
top
panel
transfect
effici
normal
luciferas
express
fig
third
panel
amount
hbv
dl
dna
isol
yidd
yldd
ysdd
yvddtransfect
cell
respect
isol
hbv
wt
fig
top
bottom
panel
howev
amount
hbv
dl
dna
yaddtransfect
cell
hbv
wt
hbv
dna
synthesi
ineffici
ykdd
yrdd
ytddtransfect
cell
hbv
dl
dna
level
hbv
wttransfect
cell
fig
top
bottom
panel
core
particl
form
compar
level
mutant
wttransfect
cell
fig
panel
next
secret
hbsag
hbcag
examin
elisa
overlap
hb
open
read
frame
orf
p
gene
lead
alter
two
amino
acid
mutant
except
yldd
chang
like
affect
hbsag
secret
agreement
previou
report
observ
reduc
hbsag
secret
cell
transfect
yadd
ykdd
ytdd
fig
level
hbsag
secret
ysddtransfect
cell
low
ysdd
mutant
harbor
att
cgg
sequenc
hb
orf
code
hbsneg
ykdd
ytdd
mutant
fig
note
ysdd
mutat
identifi
lmvresist
patient
harbor
agt
code
hb
orf
hbsag
posit
wherea
construct
mutant
harbor
tcg
contrast
previou
report
found
yrdd
mutant
secret
low
level
hbsag
replic
ineffici
fig
except
ytdd
mutant
hbcag
secret
mutant
virus
compar
hbv
wt
fig
cell
transfect
hbv
wt
ymdd
motif
mutant
twentyfour
hour
later
cell
expos
phyllanthu
extract
h
replic
intermedi
hbv
dna
isol
intracellular
core
particl
analyz
southern
blot
analysi
fig
cell
treat
lmv
adv
control
fig
lane
hbv
dl
dna
synthesi
lmv
adv
phyllanthu
extracttr
hbv
wttransfect
cell
untreat
wttransfect
cell
fig
similarli
lmv
adv
phyllanthu
extract
inhibit
hbv
dna
synthesi
yadd
ykdd
yrdd
ytddtransfect
cell
fig
f
h
consist
previou
report
hbv
dna
synthesi
yidd
yvdd
mutant
inhibit
lmv
treatment
confirm
mutant
lmvresist
fig
lane
howev
hbv
dna
synthesi
yidd
yvdd
mutant
inhibit
adv
phyllanthu
extract
fig
lane
phyllanthu
extract
mayb
use
treatment
lmvresist
chb
patient
previou
studi
demonstr
ysdd
variant
lmvresist
howev
found
hbv
dna
synthesi
ysdd
mutant
margin
inhibit
lmv
hbv
dl
dna
fig
lane
indic
addit
mutat
p
gene
might
confer
lmv
resist
nevertheless
adv
phyllanthu
extract
inhibit
hbv
dna
synthesi
ysdd
mutant
effici
lmv
fig
valu
phyllanthu
extract
hbv
wt
yidd
ysdd
yvdd
mutant
calcul
southern
blot
tabl
realtim
pcr
similar
tabl
fig
hbsag
hbcag
secret
mutant
also
determin
elisa
tabl
show
si
mutant
compar
wt
could
determin
level
hbsag
ysddtransfect
cell
secret
low
level
hbsag
taken
togeth
result
demonstr
phyllanthu
extract
inhibit
hbv
dna
synthesi
hbsag
hbcag
secret
lmvresist
mutant
medicin
deriv
plant
inhibit
viral
product
induc
inflammatori
respons
andor
product
proinflammatori
cytokin
observ
increas
express
mrna
proinflammatori
cytokin
fig
contrast
increas
express
mrna
anoth
proinflammatori
cytokin
fig
although
express
mrna
increas
hbv
wttransfectedextracttr
cell
chang
express
mrna
ifninduc
gene
oa
pkr
fig
suggest
ifn
may
exert
antivir
activ
via
transcript
upregul
ifninduc
gene
cell
system
signific
reduct
hbv
replic
increas
express
hbv
wttransfectedphyllanthu
extracttr
cell
led
us
hypothes
upregul
mrna
occur
transcript
activ
innat
immun
signal
gene
found
express
rigi
mrna
increas
hbv
wttransfectedphyllanthu
extracttr
cell
hbv
wttransfect
cell
cell
treat
extract
alon
fig
suggest
transcript
activ
innat
immun
signal
gene
also
phosphoryl
jnk
express
increas
hbv
wttransfectedextracttr
cell
hbv
wttransfect
cell
cell
treat
extract
alon
fig
result
suggest
upregul
hbvtransfectedextracttr
cell
mediat
increas
express
via
jnk
activ
increas
rigi
express
taken
togeth
data
suggest
phyllanthu
extract
inhibit
hbv
replic
cell
activ
innat
immun
respons
trigger
intracellular
signal
cascad
eg
jnk
pathway
lead
induct
phyllanthu
speci
long
util
herbal
medicin
includ
antihbv
agent
demonstr
phyllanthu
extract
antivir
activ
lmvresist
hbv
mutant
fig
tabl
also
show
antivir
activ
phyllanthu
extract
due
inhibit
intracellular
hbv
rna
c
protein
express
core
particl
format
pgrna
encapsid
fig
therefor
examin
mechan
underli
phyllanthusmedi
inhibit
hbv
dna
replic
fig
analyz
express
intracellular
signal
molecul
found
increas
express
rigi
cell
transfect
wt
hbv
expos
phyllanthu
extract
hbv
wttransfect
cell
cell
expos
extract
alon
fig
suggest
extract
trigger
innat
immun
respons
andor
inflammatori
respons
therebi
inhibit
hbv
replic
upregul
express
fig
suggest
phyllanthu
might
induc
ifnmedi
antivir
respons
via
ifninduc
oa
pkr
gene
howev
observ
oa
pkr
upregul
hbv
wttransfectedextracttr
cell
fig
sinc
cell
harbor
inher
defect
ifnmedi
antivir
respons
modestli
inhibit
hbv
replic
cell
appear
ifnmedi
respons
may
major
mechan
underli
antivir
activ
extract
howev
exclud
possibl
ifninduc
cellular
factor
apolipoprotein
b
mrnaedit
enzym
catalysi
polypeptid
human
cytidin
deaminas
may
involv
limit
hbv
replic
without
affect
pgrna
packag
express
report
human
hepatocyt
ifnrespons
element
promot
identifi
addit
dead
box
rna
helicas
involv
augment
ifnregulatori
factor
signal
interact
tankbind
kinas
kinas
sever
studi
demonstr
cellular
factor
incorpor
core
particl
interact
hbv
p
protein
therebi
inhibit
revers
transcript
hbv
x
protein
hbx
hiv
stimul
via
rasrafmitogenactiv
protein
kinas
cascad
jnk
nuclear
janu
kinasesign
transduc
activ
transcript
signal
pathway
unlik
hbx
overexpress
cell
found
express
increas
hbv
wttransfect
cell
fig
lane
sinc
upregul
express
mrna
protein
observ
hbv
wttransfectedextracttr
cell
fig
lane
express
may
trigger
hbv
replic
cell
presenc
phyllanthu
extract
upregul
express
via
activ
andor
jnk
pathway
may
play
role
observ
antivir
activ
fig
lane
regul
earli
hbv
gene
express
inhibit
hbv
replic
activ
jnk
pathway
specul
increas
express
hbv
wttransfectedphyllanthu
extracttr
cell
may
induc
express
ifninduc
gene
andor
differ
inflammatori
mediat
inhibit
hbv
replic
taken
togeth
data
present
herein
suggest
three
possibl
mechan
underli
antihbv
activ
phyllanthu
extract
phyllanthu
extract
directli
inhibit
hepadnavir
p
protein
ii
phyllanthu
extract
alon
induc
signal
cascad
cell
fig
phyllanthu
extract
work
conjunct
hbv
replic
andor
hbv
protein
rna
express
inhibit
hbv
replic
induc
express
iii
sinc
intracellular
hbv
rna
protein
core
particl
unaffect
phyllanthu
extract
fig
molecul
might
stimul
innat
immun
respons
inhibit
hbv
replic
hypothes
mutual
exclus
may
work
concert
result
present
herein
demonstr
phyllanthu
extract
effect
inhibit
replic
lmvresist
hbv
phyllanthu
extract
appear
inhibit
hbv
replic
induc
express
turn
activ
innat
immun
respons
thu
phyllanthu
extract
may
therapeut
agent
use
manag
lmvresist
chb
patient
howev
detail
antivir
mechan
vivo
efficaci
requir
investig
